X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant will enable LIfT to show how its immunomodulatory alpha neutrophils recruit immune cells in vivo to attack tumours using a new type of translational humanised mouse model.
Lead Product(s): Neutrophil-based Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding May 16, 2024
Details:
An Immunomodulatory Alpha Neutrophil (IMAN) exhibits a dual mode of action that enables them to be both exceptional cytotoxic directly and immunomodulatory to recruit the rest of the immune system also to destroy solid tumours like pancreatic cancer tumouroids.
Lead Product(s): Alpha Neutrophil-based Therapy
Therapeutic Area: Oncology Product Name: Undiclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
Pre-clinical data demonstrating that its Immunomodulatory Alpha Neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities, as it stimulated CD4, CD8, NK cells increasing tumour cell death.
Lead Product(s): Immunomodulatory Alpha Neutrophil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2023
Details:
The partnership is for the development and manufacturing of N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid tumours.
Lead Product(s): Neutrophil Progenitor-based Leukocyte Infusion Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Minaris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 16, 2023
Details:
N-LIfT (neutrophil only leukocyte infusion therapy) works by effectively transferring the innate immunity that some exceptional people naturally have in their body from their stem cells to cancer patients.
Lead Product(s): Neutrophil based Leukocyte Therapy
Therapeutic Area: Oncology Product Name: N-LIfT
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Starbloom Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
